90 related articles for article (PubMed ID: 23085828)
1. Safety and efficacy of rituximab in steroid-refractory chronic GVHD.
Clavert A; Chevallier P; Guillaume T; Delaunay J; Le Gouill S; Mahe B; Dubruille V; Gastinne T; Blin N; Moreau P; Mohty M
Bone Marrow Transplant; 2013 May; 48(5):734-6. PubMed ID: 23085828
[No Abstract] [Full Text] [Related]
2. Lack of efficacy of rituximab in refractory sclerodermatous chronic GVHD.
George L; George B; Gottlieb DJ; Hertzberg M; Fernandez-Peñas P
Bone Marrow Transplant; 2012 May; 47(5):737-8. PubMed ID: 21785472
[No Abstract] [Full Text] [Related]
3. Repeated course of rituximab for treatment of nephrotic syndrome in patients with chronic GVHD.
Mellon-Reppen S; Ratanatharathorn V; Cronin S; Uberti JP
Bone Marrow Transplant; 2010 Dec; 45(12):1758-9. PubMed ID: 20383208
[No Abstract] [Full Text] [Related]
4. Rituximab as a treatment for factor VIII inhibitor in a patient with chronic GVHD.
Wieliczka ML; Ganguly S; Abhyankar S; Lin T; McGuirk JP; Aljitawi OS
Bone Marrow Transplant; 2014 Apr; 49(4):588. PubMed ID: 24442248
[No Abstract] [Full Text] [Related]
5. Prior rituximab administration is associated with reduced rate of acute GVHD after in vivo T-cell depleted transplantation in lymphoma patients.
Crocchiolo R; Castagna L; El-Cheikh J; Helvig A; Fürst S; Faucher C; Vazquez A; Granata A; Coso D; Bouabdallah R; Blaise D
Exp Hematol; 2011 Sep; 39(9):892-6. PubMed ID: 21703987
[TBL] [Abstract][Full Text] [Related]
6. Rituximab is effective for extensive steroid-refractory chronic graft-vs.-host-disease.
Carella AM; Biasco S; Nati S; Congiu A; Lerma E
Leuk Lymphoma; 2007 Mar; 48(3):623-4. PubMed ID: 17454609
[No Abstract] [Full Text] [Related]
7. Sustained complete remission with single agent rituximab in relapsed follicular lymphoma as transformed disease after unrelated reduced intensity conditioning allogeneic stem cell transplantation.
Puig N; Caballero MD; Alcoceba M; Sebastián E; Balanzategui A; Sarasquete ME; García-Sanz R; González-Díaz M
Ann Hematol; 2011 Feb; 90(2):227-9. PubMed ID: 20506021
[No Abstract] [Full Text] [Related]
8. Rituximab in critically ill patients.
Dimopoulos G; Armaganidis A; Poulakou G; Matthaiou DK
Minerva Anestesiol; 2013 Feb; 79(2):185-93. PubMed ID: 23135691
[TBL] [Abstract][Full Text] [Related]
9. Clinical utility of rituximab in chronic graft-versus-host disease.
Bates JS; Engemann AM; Hammond JM
Ann Pharmacother; 2009 Feb; 43(2):316-21. PubMed ID: 19193571
[TBL] [Abstract][Full Text] [Related]
10. Rituximab is effective for steroid-refractory sclerodermatous chronic graft-versus-host disease.
Okamoto M; Okano A; Akamatsu S; Ashihara E; Inaba T; Takenaka H; Katoh N; Kishimoto S; Shimazaki C
Leukemia; 2006 Jan; 20(1):172-3. PubMed ID: 16239908
[No Abstract] [Full Text] [Related]
11. Rituximab monotherapy with eight weekly infusions for relapsed or refractory patients with indolent B cell non-Hodgkin lymphoma mostly pretreated with rituximab: a multicenter phase II study.
Tobinai K; Igarashi T; Itoh K; Kurosawa M; Nagai H; Hiraoka A; Kinoshita T; Uike N; Ogura M; Nawano S; Mori S; Ohashi Y;
Cancer Sci; 2011 Sep; 102(9):1698-705. PubMed ID: 21645173
[TBL] [Abstract][Full Text] [Related]
12. Rituximab and lung disease.
O'Connor MB; Phelan MJ
Ir Med J; 2012 Oct; 105(9):314. PubMed ID: 23240291
[No Abstract] [Full Text] [Related]
13. Efficacy of bendamustine in rituximab-refractory indolent B-cell non-Hodgkin lymphoma: review of a pivotal trial.
Ujjani C; Cheson B
Future Oncol; 2011 Jan; 7(1):9-14. PubMed ID: 21174533
[TBL] [Abstract][Full Text] [Related]
14. Rituximab as salvage therapy for refractory chronic GVHD.
Mohty M; Marchetti N; El-Cheikh J; Faucher C; Fürst S; Blaise D
Bone Marrow Transplant; 2008 May; 41(10):909-11. PubMed ID: 18278073
[No Abstract] [Full Text] [Related]
15. Rituximab-induced acute severe thrombocytopenia: a case series in patients with mantle cell lymphoma.
Sadashiv SK; Rao R; Fazal S; Lister J
Clin Lymphoma Myeloma Leuk; 2013 Oct; 13(5):602-5. PubMed ID: 23870855
[No Abstract] [Full Text] [Related]
16. Rituximab induced myocardial infarction: A fatal drug reaction.
Arunprasath P; Gobu P; Dubashi B; Satheesh S; Balachander J
J Cancer Res Ther; 2011; 7(3):346-8. PubMed ID: 22044821
[No Abstract] [Full Text] [Related]
17. Radioimmunotherapy with (131)I-rituximab for patients with relapsed/refractory B-cell non-Hodgkin's lymphoma (NHL).
Kang HJ; Lee SS; Kim KM; Choi TH; Cheon GJ; Kim WS; Suh C; Yang SH; Lim SM
Asia Pac J Clin Oncol; 2011 Jun; 7(2):136-45. PubMed ID: 21585693
[TBL] [Abstract][Full Text] [Related]
18. Rapid-onset, prolonged bone marrow failure following rituximab therapy of follicular lymphoma.
Debatin L; Schmitt-Graeff A; Veelken H
Onkologie; 2011; 34(6):322-4. PubMed ID: 21625186
[No Abstract] [Full Text] [Related]
19. Long-term efficacy and safety of rituximab in refractory and relapsing systemic lupus erythematosus.
Catapano F; Chaudhry AN; Jones RB; Smith KG; Jayne DW
Nephrol Dial Transplant; 2010 Nov; 25(11):3586-92. PubMed ID: 20466686
[TBL] [Abstract][Full Text] [Related]
20. Rituximab for steroid-refractory chronic graft-versus-host disease.
Cutler C; Miklos D; Kim HT; Treister N; Woo SB; Bienfang D; Klickstein LB; Levin J; Miller K; Reynolds C; Macdonell R; Pasek M; Lee SJ; Ho V; Soiffer R; Antin JH; Ritz J; Alyea E
Blood; 2006 Jul; 108(2):756-62. PubMed ID: 16551963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
